MedTrace Logo

Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.

NCT04703127 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-01-11

No results posted yet for this study

Summary

Therefore, this study will aim to assess the effectiveness and tolerability of the on-demand use of combined dapoxetine with tadalafil and combined dapoxetine with lidocaine 5% spray in treatment of patients with lifelong premature ejaculation and non-responding to dapoxetine alone.

Conditions

  • Premature Ejaculation

Interventions

DRUG

Tadalafil and Combined Dapoxietine

Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.

DRUG

Dapoxietine and Combined Lidocaine 5% Spray

Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Mohammed A El-Hamd · Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2021-01-30
Completion
2021-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703127 on ClinicalTrials.gov